Rohit Joshi, Dimitros Zardavas, Alejandra Ragone, Sandra Chica-Duque, Yang Wang, Yixi Liu, Yang Liu, Ying Cao, Brian Andrew Van Tine. "A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors: First disclosure of clinical data.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.3115